ImmuCell's Total Assets for the quarter that ended in Dec. 2023 was $43.81 Mil.
Warning Sign:
If a company builds assets at 7.7% a year, faster than its revenue growth rate of 3.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, ImmuCell's average Total Assets Growth Rate was 9.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 9.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 7.70% per year.
During the past 10 years, the average Total Assets Growth Rate was 22.60% per year.
During the past 13 years, ImmuCell's highest 3-Year average Total Assets Growth Rate was 58.10%. The lowest was -29.30%. And the median was 6.65%.
Total Assets is connected with ROA %. ImmuCell's annualizedROA % for the quarter that ended in Dec. 2023 was -10.32%. Total Assets is also linked to Revenue through Asset Turnover. ImmuCell's Asset Turnover for the quarter that ended in Dec. 2023 was 0.12.
ImmuCell Total Assets Historical Data
The historical data trend for ImmuCell's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
ImmuCell's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
ImmuCell's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
ImmuCell Total Assets Related Terms
Thank you for viewing the detailed overview of ImmuCell's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICCC has been successfully added to your 